Obsidian Therapeutics Director Peter Barrett Receives 37,653-Share Award

What Happened Peter Barrett, a director of Obsidian Therapeutics, received an award of derivative securities representing 37,653 shares on August 3, 2026. The reported acquisition price is $0.00, meaning there was no cash outlay at grant; the award will only convert to exercisable shares according to the vesting terms in the footnote.

Key Details

• Transaction date: 2026-08-03; Filing date (Form 4): 2026-08-05 (filed on time).
• Instrument: Derivative award (grant/award, code A) for 37,653 underlying shares; reported price $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The award vests and becomes exercisable on the earlier of (i) the one-year anniversary of the grant or (ii) the issuer’s next annual meeting of stockholders, contingent on Barrett’s continued service.
• No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context This is a compensation award (common for directors) rather than an open-market purchase or a sale. Because it’s a derivative award with vesting conditions, it does not represent immediately tradable shares and its realized value depends on future vesting/exercise and the company’s stock price. The filing appears timely under Form 4 rules.